Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Brands Revs Up Goody’s, BC Brands

This article was originally published in The Tan Sheet

Executive Summary

Prestige Brands is promoting Goody’s Headache Relief Shot through a deal with NASCAR and its first TV ad on ESPN. Goody’s has paved the way for further expansion into convenience stores, the company says during a sales and earnings call Nov. 7.

You may also be interested in...



Prestige Brands Invests $111m To Boost Advertising From Market Research

Prestige Brands supports leading brands including Monistat and Dramamine with promotional campaigns stemming from research into consumer preferences, says sales and marketing head Timothy Connors. With $111m ad spend, it aims to become a “preeminent marketing and sales” firm.

Prestige Brands Invests $111m To Boost Advertising From Market Research

Prestige Brands supports leading brands including Monistat and Dramamine with promotional campaigns stemming from research into consumer preferences, says sales and marketing head Timothy Connors. With $111m ad spend, it aims to become a “preeminent marketing and sales” firm.

Merck Reaffirms Commitment To Consumer Care In Restructuring

Merck says it remains committed to retaining consumer care and animal health, though it continues to evaluate the businesses. Competitors such as Pfizer and Bristol-Myers Squibb successfully spun out non-pharma assets following similar restructurings.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel